Crossmark

Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale

Crossref DOI link: https://doi.org/10.1007/s13300-018-0480-7

Published Online: 2018-08-10

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kubota, Yoshiaki

Yamamoto, Takeshi

Tara, Shuhei

Tokita, Yukichi

Yodogawa, Kenji

Iwasaki, Yuki

Takano, Hitoshi

Tsukada, Yayoi

Asai, Kuniya

Miyamoto, Masaaki

Miyauchi, Yasushi

Kodani, Eitaro

Sato, Naoki

Tanabe, Jun

Shimizu, Wataru
Funding

Funding for this research was provided by:

Boehringer Ingelheim

Eli Lilly and Company
License Information

Text and Data Mining valid from 2018-08-10

Version of Record valid from 2018-08-10
More Information

Article History

Received: 7 July 2018

First Online: 10 August 2018

Document is current

Any future updates will be listed below